Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 1:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,061 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Metabolism, Drug Clear all
Completed Phase 1 Interventional

A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis

NCT00002321
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Aldesleukin
Drug
Lead sponsor
Chiron Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 15, 2026, 1:02 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Dietary Supplements on Muscle Mass and Function While Using GLP-1 Medication

NCT07806838
View directory record Official record
Conditions
Obesity & Overweight, Muscle Mass and Strength, Muscle Function
Interventions
Whey Protein Supplementation, Maltodextrin Placebo Capsules, Mixed Spice Capsules
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 15, 2026, 1:02 AM EDT
Completed Phase 3 Interventional

REVEAL - Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis

NCT06788535
View directory record Official record
Conditions
Cardiac Amyloidosis
Interventions
I-124 evuzamitide
Drug
Lead sponsor
Sharmila Dorbala
Other
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
20
States / cities
Scottsdale, Arizona • Duarte, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 15, 2026, 1:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Patient Safety Learning Laboratory: Making Acute Care More Patient-Centered

NCT02969343
View directory record Official record
Conditions
Central Line-Associated Bloodstream Infection (CLABSI), Venous Thromboembolism, Patient Fall, Catheter-Associated Infection, Severe Hypoglycemia, Opioid-Related Severe Adverse Drug Event, Hospital Acquired Pressure Ulcer, Adverse Drug Event, Severe Hospital Acquired Delerium, Rapid Response Related to Arrhythmia
Interventions
Patient Safety health information technology
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
21,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Sep 15, 2026, 1:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy Adults

NCT07513571
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD4954, Laroprovstat
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 15, 2026, 1:02 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Imaging Lymphatic Function in Normal Subjects and in Persons With Lymphatic Disorders

NCT00833599
View directory record Official record
Conditions
Lymphedema, Lymphatic Disorders, Lipedema, Vascular Malformation, Vascular Anomaly, Dercum Disease
Interventions
NIRFLI with ICG
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
3 Months and older
Enrollment
283 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2030
U.S. locations
3
States / cities
Houston, Texas • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 15, 2026, 1:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism

NCT00135434
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir/Ritonavir/Lopinavir/ritonavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Hamilton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 7, 2011 · Synced Sep 15, 2026, 1:02 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Comparative Study to Evaluate KADIAN and Avinza in Healthy Adults

NCT00782548
View directory record Official record
Conditions
Healthy
Interventions
KADIAN (morphine sulfate sustained-release) capsules, Avinza (morphine sulfate sustained-release) capsules
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
19 Years to 40 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Sep 15, 2026, 1:02 AM EDT
Completed Phase 2Phase 3 Interventional

Secondary Prevention of Osteoporotic Fractures in Residents of Long-Term Care Facilities

NCT00280943
View directory record Official record
Conditions
Hip Fractures, Osteoporosis
Interventions
Long-term care facilities in the intervention arm will receive education and feedback audit on performance
Behavioral
Lead sponsor
Duke University
Other
Eligibility
50 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Sep 15, 2026, 1:02 AM EDT
Completed Not applicable Interventional

Improving Medication Adherence in Comorbid Conditions

NCT00072891
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hypertension, Hyperlipidemia
Interventions
telephone counseling
Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
40 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 14, 2010 · Synced Sep 15, 2026, 1:02 AM EDT
Completed Not applicable Interventional

Evaluation of the Impact of a Food is Medicine Program on Diabetes-related Health Outcomes for People With Type 2 Diabetes in a Low Income Community-based Setting Compared to Usual Care

NCT07529184
View directory record Official record
Conditions
Diabetes (DM)
Interventions
Food is medicine
Dietary Supplement
Lead sponsor
Public Health Institute Center for Wellness and Nutrition
Other
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Stockton, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 15, 2026, 1:02 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Weight and/or Obesity on Ethambutol Drug Concentrations

NCT01048697
View directory record Official record
Conditions
Obesity, Tuberculosis
Interventions
Ethambutol
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Sep 15, 2026, 1:02 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity

NCT07013643
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD6234, Ethinyl estradiol/Levonorgestrel (EE/LEVO), Acetaminophen (APAP), AZD9550
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
35 Years to 75 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 15, 2026, 1:02 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Abriendo Caminos 2: Clearing the Path to Hispanic Health

NCT03505658
View directory record Official record
Conditions
Obesity, Childhood Obesity, Nutrient; Excess, Community Health Education
Interventions
Education and Behavior
Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
6 Years to 18 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
4
States / cities
Fresno, California • Urbana, Illinois • Ames, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2019 · Synced Sep 15, 2026, 1:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants

NCT06186622
View directory record Official record
Conditions
Healthy, Obese, Overweight
Interventions
Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, Midazolam, Sodium Bicarbonate
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 15, 2026, 1:02 AM EDT
Completed Phase 2 Interventional Results available

Thiamine as a Renal Protective Agent in Septic Shock

NCT03550794
View directory record Official record
Conditions
Sepsis, Kidney Injury, Thiamine Deficiency
Interventions
Thiamine Hydrochloride, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Boston, Massachusetts • Manhasset, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Sep 15, 2026, 1:02 AM EDT
Completed Not applicable Interventional

Mobile Health Behavioral Intervention in Patients With Heart Failure and Diabetes Mellitus

NCT02918175
View directory record Official record
Conditions
Diabetes Mellitus, Heart Failure
Interventions
mHealth
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
Stanford, California • Boston, Massachusetts • Brooklyn, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Sep 15, 2026, 1:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Increasing Vegetable Intake Using Monosodium Glutamate: A Reduced-Effort Intervention

NCT05591612
View directory record Official record
Conditions
Healthy Nutrition, Culinary Medicine, Sodium Excess
Interventions
Salt replacement seasoning (50% salt and 50% MSG) mix, Salt replacement seasoning (70% salt and 30% MSG) mix, NaCl (sodium chloride/table salt)
Behavioral
Lead sponsor
Texas Tech University
Other
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Sep 15, 2026, 1:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults.

NCT03927677
View directory record Official record
Conditions
Gout, Hyperuricemia
Interventions
Xanthine Oxidase Inhibitor
Drug
Lead sponsor
LG Chem
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Sep 15, 2026, 1:02 AM EDT
Completed Not applicable Interventional

Virtual Lifestyle Medicine Comparative Effectiveness Research

NCT03731481
View directory record Official record
Conditions
Chronic Disease, Obesity, Sleep Disorder, Depression
Interventions
Lifestyle Medicine
Behavioral
Lead sponsor
Ohio University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Athens, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Sep 15, 2026, 1:02 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes

NCT06419777
View directory record Official record
Conditions
Gestational Diabetes, Pregnancy Related
Interventions
Insulin
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
430 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Rochester, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Sep 15, 2026, 1:02 AM EDT
Terminated Phase 1 Interventional

A Study to Determine Safety and Efficacy of (REMD-477) in Controlling Hyperglycemia Due to Copanlisib

NCT04253223
View directory record Official record
Conditions
Hyperglycemia Drug Induced
Interventions
REMD-477
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 15, 2026, 1:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of KADIAN 100 mg When Dosed With Alcohol Under Fasting and Fed Conditions Compared to Water

NCT00768183
View directory record Official record
Conditions
Healthy
Interventions
KADIAN Capsule + alcohol (under fasting conditions), KADIAN Capsule + water (under fasting conditions), morphine sulfate IR oral solution + water, KADIAN Capsule + alcohol (under fed conditions)
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
21 Years to 40 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Sep 15, 2026, 1:02 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

NCT01719003
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hyperglycemia
Interventions
Metformin 500 mg bid, Metformin 1000 mg bid, Empagliflozin low dose qd, Empagliflozin high dose qd, Empagliflozin low dose bid, Empagliflozin high dose bid
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
41
States / cities
Birmingham, Alabama • Manley Hot Springs, Alaska • Glendale, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2016 · Synced Sep 15, 2026, 1:02 AM EDT